Physician profile
Mark A Epstein
NPI 1376613430
$64,065.92
in general payments reported to CMS, 2019-2025
31 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $274 · 2021: $12K · 2022: $20K · 2023: $13K · 2024: $16K · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,747 · Honoraria: $3,250 · Travel and Lodging: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,432.00 |
| Food and Beverage | $3,747.23 |
| Honoraria | $3,250.00 |
| Travel and Lodging | $3,098.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $45,550.51 | 2019-2024 | Qelbree, Qelbree |
| Neurelis, INC. | $10,855.07 | 2021-2024 | Valtoco |
| Livanova USA, INC. | $3,017.68 | 2019-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $975.63 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Aquestive Therapeutics, INC. | $659.02 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $565.52 | 2022-2025 | |
| Corium, LLC | $369.60 | 2021-2025 | Azstarys |
| Eisai INC. | $241.62 | 2019-2023 | |
| Tris Pharma INC | $210.83 | 2019-2025 | Dyanavel Xr |
| Greenwich Biosciences, INC. | $202.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $170.47 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $156.83 | 2023 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $151.96 | 2023-2024 | Fycompa |
| Ironshore Pharmaceuticals INC. | $145.59 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $108.85 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.04 | 2019-2020 | |
| Allergan, INC. | $97.77 | 2019-2022 | |
| Neos Therapeutics, Lp | $94.75 | 2019-2020 | |
| Aprecia Pharmaceuticals, LLC | $56.92 | 2022-2023 | Spritam |
| Sk Life Science, INC. | $48.84 | 2020-2022 | |
| Tepha INC | $45.56 | 2019 | |
| Aucta Pharmaceuticals, INC. | $42.29 | 2025 | Motpoly Xr |
| Upsher-Smith Laboratories LLC | $39.36 | 2019 | |
| Cranial Technologies, INC | $29.60 | 2019 | |
| Biocodex, INC. | $24.30 | 2023 | Diacomit |
| Lilly USA, LLC | $20.71 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.36 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.45 | 2019 | |
| Shire North American Group INC | $14.93 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.60 | 2023 | Lyvispah |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.